-
-
-
-
-
-
-
Synergy Pharma (SGYP): Trulance IBS-C sNDA Accepted - Cantor
-
-
-
-
-
-
-
Synergy Pharmaceuticals Announces Positive Results in First Phase 3 Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
-
-
-
-
-
-
-
BTIG Affirms 'Buy' Rating on Synergy Pharma (SGYP) Ahead of Pivotal Plecanatide Data in IBS-C
-
-
-
-
-
-
-
Synergy's (SGYP) Plecanatide Seen as 'Rare Gem' at Roth Capital
-
-
-
-
-
15,466 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

